<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04799353</url>
  </required_header>
  <id_info>
    <org_study_id>M19-972</org_study_id>
    <nct_id>NCT04799353</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and How the Body Handles a Single Dose of Subcutaneous (SC) and Intravenous (IV) Budigalimab in Adult Participants Living With Human Immunodeficiency Virus (HIV)</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-controlled Single-Dose Phase 1b Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous and Intravenous Administration of Budigalimab in Adult People Living With HIV-1 (PLWH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate how safe Budigalimab is and how it moves within the body in adult&#xD;
      participants with HIV-1 infection.&#xD;
&#xD;
      Budigalimab is an investigational drug being evaluated for the treatment of Human&#xD;
      Immunodeficiency Virus. Study participants will be assigned to one of the 4 treatment groups&#xD;
      and will receive a single dose of Budigalimab or placebo subcutaneous (SC) and intravenous&#xD;
      (IV). Around 32 participants 18-65 years of age living with Human Immunodeficiency Virus will&#xD;
      be enrolled in the study in approximately 9 sites worldwide.&#xD;
&#xD;
      Each participant will receive single dose of SC and IV Budigalimab and/or Placebo on day 1&#xD;
      and will be followed for 24 weeks.&#xD;
&#xD;
      Participants will attend weekly to every two and every four weeks visits during the study at&#xD;
      a hospital. The effect of the treatment will be checked by medical assessments, blood tests&#xD;
      and checking for side effects. There may be higher treatment burden for participants in this&#xD;
      trial.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 15, 2021</start_date>
  <completion_date type="Anticipated">October 2, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Experiencing Study Drug-Related Grade 3 or Higher Adverse Events (AEs)</measure>
    <time_frame>Up to approximately 24 weeks</time_frame>
    <description>An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of the study drug as either having a reasonable possibility or no reasonable possibility. AEs are given a grade from 1-5 with Grade 3 being severe but not life-threatening and requiring hospitalization, Grade 4 being life-threatening requiring immediate intervention and Grade 5 being death related to an AE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Study Drug-Related Immune-Related Adverse Events (IRAE)</measure>
    <time_frame>Up to approximately 24 weeks</time_frame>
    <description>Assessed using the American Society of Clinical Oncology (ASCO) IRAE management guidelines [which utilizes the National Institutes of Health (NIH) Common Terminology Criteria for Adverse Events (CTCAE) grading scale] but modified, as applicable, according to the NIH Division of AIDS (DAIDS) (v2.1) AE grading scale.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Serum Concentration (Cmax)</measure>
    <time_frame>Up to approximately 24 weeks</time_frame>
    <description>Maximum Serum Concentration (Cmax) of Budigalimab.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Observed Plasma Concentration (Tmax)</measure>
    <time_frame>Up to approximately 24 weeks</time_frame>
    <description>Time to Maximum Observed Plasma Concentration (Tmax) of Budigalimab.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve (AUC) of Budigalimab in Plasma</measure>
    <time_frame>Up to approximately 24 weeks</time_frame>
    <description>Area Under the Plasma Concentration-time Curve (AUC).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Phase Elimination Half-life (t1/2) of Budigalimab in Plasma</measure>
    <time_frame>Up to approximately 24 weeks.</time_frame>
    <description>Terminal phase elimination half-life (t1/2)</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Human Immunodeficiency Virus (HIV)</condition>
  <arm_group>
    <arm_group_label>Group 1: Placebo SC + Placebo IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Subcutaneous (SC) Placebo, followed by Intravenous (IV) Placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Budigalimab (SC) + Placebo IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Subcutaneous (SC) Budigalimab, followed by Intravenous (IV) Placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: Budigalimab SC + Placebo IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Subcutaneous (SC) Budigalimab, followed by Intravenous (IV) Placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4: Placebo SC + Budigalimab IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Subcutaneous (SC) Placebo, followed by IV Budigalimab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budigalimab</intervention_name>
    <description>Subcutaneous (SC)</description>
    <arm_group_label>Group 2: Budigalimab (SC) + Placebo IV</arm_group_label>
    <arm_group_label>Group 3: Budigalimab SC + Placebo IV</arm_group_label>
    <other_name>ABBV-181</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subcutaneous (SC)</description>
    <arm_group_label>Group 1: Placebo SC + Placebo IV</arm_group_label>
    <arm_group_label>Group 4: Placebo SC + Budigalimab IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budigalimab</intervention_name>
    <description>Intravenous (IV)</description>
    <arm_group_label>Group 4: Placebo SC + Budigalimab IV</arm_group_label>
    <other_name>ABBV-181</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenous (IV)</description>
    <arm_group_label>Group 1: Placebo SC + Placebo IV</arm_group_label>
    <arm_group_label>Group 2: Budigalimab (SC) + Placebo IV</arm_group_label>
    <arm_group_label>Group 3: Budigalimab SC + Placebo IV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Condition of generally good health, body mass index ≥ 18.0 to &lt; 35.0 kg/m2.&#xD;
&#xD;
          -  Laboratory values must meet acceptable criteria.&#xD;
&#xD;
          -  Human Immunodeficiency Virus (HIV-1) infected on antiretroviral therapy (ART) for at&#xD;
             least 12 months prior to screening and on current ART regimen for at least 8 weeks&#xD;
             prior to screening.&#xD;
&#xD;
          -  CD4 cell count ≥ 450 cells/μL at Screening and during the 12 months prior to&#xD;
             Screening.&#xD;
&#xD;
          -  Plasma HIV-1 RNA below the lower limit of quantification at Screening and at least 6&#xD;
             months prior to Screening.&#xD;
&#xD;
          -  Participants agreeing to use an effective barrier method of protection (male and/or&#xD;
             female condom) during sexual activity from Study Day 1 through last study visit for&#xD;
             the purposes of prevention of HIV transmission.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants with signs/symptoms associated with SARS-CoV-2 infection OR Current&#xD;
             SARS-CoV-2 infection by any viral nucleic acid test completed within 7 days prior to&#xD;
             the Day 1 dose.&#xD;
&#xD;
          -  Participants having history or ongoing diagnosis of acquired immunodeficiency syndrome&#xD;
             (AIDS)-defining illness.&#xD;
&#xD;
          -  Participants having history of or active immunodeficiency (other than HIV).&#xD;
&#xD;
          -  Participants having active autoimmune disease or history of autoimmune disease that&#xD;
             has required systemic treatment.&#xD;
&#xD;
          -  Prior therapy/exposure to budigalimab or any other immune checkpoint inhibitor [e.g.,&#xD;
             anti-programmed cell death protein 1(PD-1), anti-PD-L1, anti-PD-L2, anti-CTLA4].&#xD;
&#xD;
          -  Participants having clinically significant medical disorders that might expose the&#xD;
             subjects to undue risk of harm, confound study outcomes, or prevent the subject from&#xD;
             completing the study.&#xD;
&#xD;
          -  Participants having active or suspected malignancy or history of malignancy (other&#xD;
             than basal cell skin cancer or cervical carcinoma in situ) in the past 5 years.&#xD;
&#xD;
          -  Participants with history of or active tuberculosis (TB) at screening.&#xD;
&#xD;
          -  Participants having known psychiatric or substance abuse disorders that would&#xD;
             interfere with adherence to study requirements.&#xD;
&#xD;
          -  Participants who have received immunomodulatory or immunosuppressive (including&#xD;
             IV/orally administered [PO] steroids at any dose, but excluding steroids that are&#xD;
             inhaled, topical or via local injection) therapy within 24 weeks prior to the first&#xD;
             dose of study drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ABBVIE INC.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>844-663-3742</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Franco Felizarta, Md /Id# 223931</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ruane Clinical Research Group /ID# 224496</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Quest Clinical Research /ID# 223925</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115-3037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Central Texas Clinical Research /ID# 223937</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705-3326</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Hope Foundation, Inc. /ID# 224492</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401-4528</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>North TX Infectious Diseases /ID# 224494</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Crofoot Research Center, Inc /ID# 224493</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77098-3900</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Peter Shalit, M.D. /ID# 224801</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104-3595</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ponce Medical School Foundation /ID# 224230</name>
      <address>
        <city>Ponce</city>
        <zip>00716-0377</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Puerto Rico AIDS Clinical Trials Unit CRS /ID# 223936</name>
      <address>
        <city>San Juan</city>
        <zip>00935</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 12, 2021</study_first_submitted>
  <study_first_submitted_qc>March 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2021</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Human Immunodeficiency Virus (HIV)</keyword>
  <keyword>Budigalimab</keyword>
  <keyword>ABBV-181</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

